This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
And despite major regulatory wins since late 2023, the biotech hasn't recovered: The stock is down 23% year to date. Can CRISPR Therapeutics bounce back? Some recent developments could move the needle for the gene-editing specialist down the road. Let's find out what they are and what they mean for investors. Expanded coverage for CRISPR Therapeutics' crown jewel Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. The list includes the U.S., the U.K., the European Union, Saudi Arabia, and Bahrain. Casgevy, developed with Vertex Pharmaceuticals , treats sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Both are rare blood disorders with few treatment options. Gene-editing techniques allowed researchers to create onetime cures for them -- that's what Casgevy is. However, gene-editing medicines have a significant disadvantage. Due to the complexity of manufacturing
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025? [Yahoo! Finance]Yahoo! Finance
- 1 big new Green Flag for CRISPR Therapeutics' Stock [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $86.00 price target on the stock.MarketBeat
- Capsida Biotherapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Celebrating a Milestone: Engineering Tomorrow Reaches 1 Million Students [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 11/5/24 - Beat
CRSP
Sec Filings
- 12/10/24 - Form SC
- 12/4/24 - Form 4
- 11/13/24 - Form 4
- CRSP's page on the SEC website